A prospective ramdomized control trial of comparing PPI vesus P-CAB in the treatment of hemorrhagic peptic ulcer disease

A prospective ramdomized control trial of comparing PPI vesus P-CAB in the treatment of hemorrhagic peptic ulcer disease - PPI versus P-CAB in the treatment of hemorrhagic peptic ulcer

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021992

Enrollment

Registered

2016-04-20

Start date

2016-04-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemorrhagic peptic ulcer

Interventions

The patients of hemorrhagic peptic ulcer are treated by PPI, after endoscopic hemostasis Tht patients of hemorrhagic peptic ulcer are treated by P-CAB, after endoscopic hemostasis

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients of hemorragic peptic ulcer are done endoscopic hemostasis. The patients who agree with this study.

Exclusion criteria

Exclusion criteria: The patients of hemorrhagic peptic ulcer are hard to do endoscopic hemostasis. The patients can not take medicine. The patients who do not agree with this study. Tha patients who take atazanavir sulfate or rirupibirin hydrochloride.

Design outcomes

Primary

Measure	Time frame
The reduction rate of ulcer for a week	—

Secondary

Measure	Time frame
The rate of re-bleeding, the day of hospitalization, the rate of blood transfusion, The transfer rate of surgery or IVR, The influence of anti-platelet/anti-coaglant,The cure rate for 28 days, The cure rate for 56 days	—

Countries

Japan

Contacts

Public ContactMasahide Ebi

Aichi medical university Department of Gastroentelorogy

mebi@aichi-med-u.ac.jp0561-62-3311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026